Literature DB >> 25332967

FGFR1 as a novel prognostic and predictive biomarker in squamous cell cancers of the lung and the head and neck area.

Anne von Mässenhausen1, Alina Franzen1, Lynn Heasley1, Sven Perner1.   

Abstract

FGFR1 amplification is a genomic aberration recently identified in various types of cancer. Especially squamous cell carcinomas of the lung and the head and neck show this genetic alteration in high frequencies. In these cancers FGFR1 is not only a therapeutic target but does also serve as a biomarker that correlates with parameters of worse outcome. However, since FGFR1 amplification does not always correlate with high protein expression defining the best predictive biomarker for a FGFR1 targeted therapy is of great importance.

Entities:  

Keywords:  FGFR1; biomarker; head and neck cancer; lung cancer; therapeutic target

Year:  2013        PMID： 25332967      PMCID： PMC4200677          DOI： 10.3978/j.issn.2305-5839.2013.06.08

Source DB:  PubMed          Journal:  Ann Transl Med        ISSN： 2305-5839


  9 in total

1.  Recurrent FGFR1 amplification and high FGFR1 protein expression in oral squamous cell carcinoma (OSCC).

Authors:  Kolja Freier; Carsten Schwaenen; Carsten Sticht; Christa Flechtenmacher; Joachim Mühling; Christof Hofele; Bernhard Radlwimmer; Peter Lichter; Stefan Joos
Journal:  Oral Oncol       Date:  2006-06-27       Impact factor: 5.337

2.  Frequent and focal FGFR1 amplification associates with therapeutically tractable FGFR1 dependency in squamous cell lung cancer.

Authors:  Jonathan Weiss; Martin L Sos; Danila Seidel; Martin Peifer; Thomas Zander; Johannes M Heuckmann; Roland T Ullrich; Roopika Menon; Sebastian Maier; Alex Soltermann; Holger Moch; Patrick Wagener; Florian Fischer; Stefanie Heynck; Mirjam Koker; Jakob Schöttle; Frauke Leenders; Franziska Gabler; Ines Dabow; Silvia Querings; Lukas C Heukamp; Hyatt Balke-Want; Sascha Ansén; Daniel Rauh; Ingelore Baessmann; Janine Altmüller; Zoe Wainer; Matthew Conron; Gavin Wright; Prudence Russell; Ben Solomon; Elisabeth Brambilla; Christian Brambilla; Philippe Lorimier; Steinar Sollberg; Odd Terje Brustugun; Walburga Engel-Riedel; Corinna Ludwig; Iver Petersen; Jörg Sänger; Joachim Clement; Harry Groen; Wim Timens; Hannie Sietsma; Erik Thunnissen; Egbert Smit; Daniëlle Heideman; Federico Cappuzzo; Claudia Ligorio; Stefania Damiani; Michael Hallek; Rameen Beroukhim; William Pao; Bert Klebl; Matthias Baumann; Reinhard Buettner; Karen Ernestus; Erich Stoelben; Jürgen Wolf; Peter Nürnberg; Sven Perner; Roman K Thomas
Journal:  Sci Transl Med       Date:  2010-12-15       Impact factor: 17.956

Review 3.  ALK inhibition for non-small cell lung cancer: from discovery to therapy in record time.

Authors:  David E Gerber; John D Minna
Journal:  Cancer Cell       Date:  2010-12-14       Impact factor: 31.743

4.  Rationale for treatment of metastatic squamous cell carcinoma of the lung using fibroblast growth factor receptor inhibitors.

Authors:  Friederike Göke; Alina Franzen; Roopika Menon; Diane Goltz; Robert Kirsten; Diana Boehm; Wenzel Vogel; Antonia Göke; Veit Scheble; Joerg Ellinger; Ulrich Gerigk; Falko Fend; Patrick Wagner; Andreas Schroeck; Sven Perner
Journal:  Chest       Date:  2012-10       Impact factor: 9.410

5.  Fibroblast growth factor receptor 1 amplification is a common event in squamous cell carcinoma of the head and neck.

Authors:  Friederike Göke; Maike Bode; Alina Franzen; Robert Kirsten; Diane Goltz; Antonia Göke; Rakesh Sharma; Diana Boehm; Wenzel Vogel; Patrick Wagner; Claudia Lengerke; Glen Kristiansen; Jutta Kirfel; Tobias Van Bremen; Friedrich Bootz; Lynn E Heasley; Andreas Schröck; Sven Perner
Journal:  Mod Pathol       Date:  2013-04-26       Impact factor: 7.842

6.  Determining the profiles and parameters for gene amplification testing of growth factor receptors in lung cancer.

Authors:  Eva Pros; Sylvie Lantuejoul; Lydia Sanchez-Verde; Sandra D Castillo; Ester Bonastre; Ana Suarez-Gauthier; Esther Conde; Juan C Cigudosa; Fernando Lopez-Rios; Juan Torres-Lanzas; Josep Castellví; Santiago Ramon y Cajal; Elisabeth Brambilla; Montse Sanchez-Cespedes
Journal:  Int J Cancer       Date:  2013-03-09       Impact factor: 7.396

Review 7.  Cellular responses to EGFR inhibitors and their relevance to cancer therapy.

Authors:  Pinaki R Dutta; Amit Maity
Journal:  Cancer Lett       Date:  2007-03-23       Impact factor: 8.679

8.  Fibroblast growth factor receptor 1 gene amplification is associated with poor survival and cigarette smoking dosage in patients with resected squamous cell lung cancer.

Authors:  Hye Ryun Kim; Dae Joon Kim; Dae Ryong Kang; Jin Gu Lee; Sun Min Lim; Chang Young Lee; Sun Young Rha; Mi Kyung Bae; Young Joo Lee; Se Hoon Kim; Sang-Jun Ha; Ross Andrew Soo; Kyung Young Chung; Joo Hang Kim; Ji Hyun Lee; Hyo Sup Shim; Byoung Chul Cho
Journal:  J Clin Oncol       Date:  2012-11-26       Impact factor: 44.544

9.  Inhibitor-sensitive FGFR1 amplification in human non-small cell lung cancer.

Authors:  Amit Dutt; Alex H Ramos; Peter S Hammerman; Craig Mermel; Jeonghee Cho; Tanaz Sharifnia; Ajit Chande; Kumiko Elisa Tanaka; Nicolas Stransky; Heidi Greulich; Nathanael S Gray; Matthew Meyerson
Journal:  PLoS One       Date:  2011-06-07       Impact factor: 3.240
  9 in total
  9 in total

1.  The genomic landscape of UM-SCC oral cavity squamous cell carcinoma cell lines.

Authors:  Megan L Ludwig; Aditi Kulkarni; Andrew C Birkeland; Nicole L Michmerhuizen; Susan K Foltin; Jacqueline E Mann; Rebecca C Hoesli; Samantha N Devenport; Brittany M Jewell; Andrew G Shuman; Matthew E Spector; Thomas E Carey; Hui Jiang; J Chad Brenner
Journal:  Oral Oncol       Date:  2018-11-08       Impact factor: 5.337

2.  Therapeutic Targeting of FGFR Signaling in Head and Neck Cancer.

Authors:  Zechen Wang; Karen S Anderson
Journal:  Cancer J       Date:  2022 Sep-Oct 01       Impact factor: 2.074

3.  Prognostic and clinicopathological significance of FGFR1 gene amplification in resected esophageal squamous cell carcinoma: a meta-analysis.

Authors:  Yan Wang; Yanming Wu; Jialong Li; Yutian Lai; Kun Zhou; Guowei Che
Journal:  Ann Transl Med       Date:  2019-11

4.  The Role of FGFR1 Gene Amplification as a Poor Prognostic Factor in Squamous Cell Lung Cancer: A Meta-Analysis of Published Data.

Authors:  Yang Wang; Wen Gao; Jiali Xu; Xiaojun Chen; Yang Yang; Yizhi Zhu; Yongmei Yin; Renhua Guo; Ping Liu; Yongqian Shu; Lingxiang Liu
Journal:  Biomed Res Int       Date:  2015-12-16       Impact factor: 3.411

5.  Deep sequencing of human papillomavirus positive loco-regionally advanced oropharyngeal squamous cell carcinomas reveals novel mutational signature.

Authors:  Christian Grønhøj; David H Jensen; Tina Agander; Katalin Kiss; Estrid Høgdall; Lena Specht; Frederik Otzen Bagger; Finn Cilius Nielsen; Christian von Buchwald
Journal:  BMC Cancer       Date:  2018-06-07       Impact factor: 4.430

6.  High amplification of FGFR1 gene is a delayed poor prognostic factor in early stage ESCC patients.

Authors:  Qi Song; Yalan Liu; Dongxian Jiang; Haixing Wang; Jie Huang; Yifan Xu; Akesu Sujie; Haiying Zeng; Chen Xu; Yingyong Hou
Journal:  Oncotarget       Date:  2017-08-12

7.  Small molecule profiling to define synergistic EGFR inhibitor combinations in head and neck squamous cell carcinoma.

Authors:  Nicole L Michmerhuizen; Megan L Ludwig; Andrew C Birkeland; Sai Nimmagadda; Jingyi Zhai; Jiayu Wang; Brittany M Jewell; Dylan Genouw; Lindsay Remer; Daniel Kim; Susan K Foltin; Apurva Bhangale; Aditi Kulkarni; Carol R Bradford; Paul L Swiecicki; Thomas E Carey; Hui Jiang; J Chad Brenner
Journal:  Head Neck       Date:  2022-02-27       Impact factor: 3.821

8.  Prognostic roles for fibroblast growth factor receptor family members in malignant peripheral nerve sheath tumor.

Authors:  Wenya Zhou; Xiaoling Du; Fengju Song; Hong Zheng; Kexin Chen; Wei Zhang; Jilong Yang
Journal:  Oncotarget       Date:  2016-04-19

9.  Fibroblast growth factor receptor 1 gene amplification and protein expression in human lung cancer.

Authors:  Omar Elakad; Anna-Maria Lois; Katja Schmitz; Sha Yao; Sara Hugo; Laura Lukat; Marc Hinterthaner; Bernhard C Danner; Alexander von Hammerstein-Equord; Kirsten Reuter-Jessen; Hans-Ulrich Schildhaus; Philipp Ströbel; Hanibal Bohnenberger
Journal:  Cancer Med       Date:  2020-03-24       Impact factor: 4.452
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.